Aura Biosciences Shares Phase 2 Data at The Retina Society Annual Meeting
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm dedicated to precision therapies for solid tumors, has announced its participation in The Retina Society Annual Meeting. This event will take place from September 11-15, during which the company will present the end-of-study data from its Phase 2 trial on the suprachoroidal administration of bel-sar, a treatment designed for patients with early-stage choroidal melanoma and indeterminate lesions.
Details of the Presentation
The presentation will showcase important findings from the Phase 2 clinical trial, focusing on the efficacy and safety of bel-sar, also referred to as Belzupacap Sarotalocan (AU-011). Dr. Ivana Kim, MD, from Mass Eye and Ear, will lead the session.
Title: Final Results of a Phase 2 Trial of Suprachoroidal Administration of Bel-sar for Choroidal Melanoma
Presenter: Dr. Ivana Kim, MD, Mass Eye and Ear
Date/Time: Thursday, September 12, from 11:04 am to 11:09 am Western European Daylight Time (6:04 am to 6:09 am Eastern Time)
Following the live session, a recording of the presentation will be made available, allowing interested individuals to revisit the findings and discussions at their convenience.
Virtual Investor Event
Alongside the presentation, Aura Biosciences will conduct a virtual ocular oncology investor event featuring Dr. Kim and Dr. Prithvi Mruthyunjaya from Stanford University. This session will explore the Phase 2 end-of-study data and its implications for ocular oncology.
The investor event is scheduled for Thursday, September 12, at 8:00 am Eastern Time. It will include a live Q&A segment, promoting interaction between the physicians and attendees.
The webcast will also be accessible on Aura's website in the “Investors & Media” section, where it will remain available for 90 days after the event.
Insights from Renowned Presenters
Dr. Ivana K. Kim, MD, is a leading figure in the retina service at Mass Eye and Ear, where she specializes in complex conditions such as retinal detachment and uveal melanoma. Additionally, she serves as Co-Director at the Harvard Ophthalmology AMD Center of Excellence, where she is actively advancing treatments for age-related macular degeneration (AMD).
Her extensive training at Harvard Medical School, combined with her rich experience, significantly enhances both the quality of care she provides and the research initiatives she leads.
Dr. Prithvi Mruthyunjaya, MD, MHS, is the Director of Ocular Oncology at Stanford University's Byers Eye Institute. He is well-regarded for his dual expertise in ophthalmology and radiation oncology and is pioneering research in ocular cancer imaging and genetic studies.
Aura Biosciences' Research Innovations
Aura's mission is to develop therapies that preserve organ function while effectively combating cancer. Their lead candidate, bel-sar, is currently involved in pivotal trials targeting primary choroidal melanoma and other ocular malignancies.
Additionally, the company is investigating bel-sar's potential for treating bladder cancer, demonstrating its commitment to expanding its therapeutic offerings. The ongoing global Phase 3 CoMpass trial is particularly noteworthy as it seeks to establish bel-sar as a first-line treatment option for adults with early-stage choroidal melanoma.
About Aura Biosciences
Aura Biosciences is at the cutting edge of biotechnology, revolutionizing the treatment of solid tumors. With a focus on precision therapies, the company is dedicated to improving survival rates and enhancing the quality of life for patients.
Based in Boston, Aura continues to make significant advancements in ocular oncology while maintaining a robust clinical development portfolio. The company is committed to fostering social visibility and engagement through its online platforms.
Contact Information
For further inquiries, Alex Dasalla is the Head of Investor Relations and Corporate Communications. Interested individuals can reach out via email at IR@aurabiosciences.com.
Frequently Asked Questions
What is the focus of the Phase 2 study presented by Aura Biosciences?
The Phase 2 study evaluates the efficacy and safety of suprachoroidal administration of bel-sar in treating early-stage choroidal melanoma.
Who are the key presenters for the upcoming event?
Dr. Ivana Kim and Dr. Prithvi Mruthyunjaya will present and discuss the findings at the Retina Society Annual Meeting and the virtual investor event.
How can I access the presentation details?
The presentation will be available online after the event, ensuring that the information can be accessed by those who missed the live session.
What is the significance of the bel-sar treatment?
Bel-sar aims to provide a vision-sparing therapy for patients with ocular melanoma, offering a potential alternative to traditional treatments that may compromise organ function.
Where can I find more information about Aura Biosciences?
More information about Aura and its innovative therapies can be found at their official website aurabiosciences.com.